Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China

Authors: Ying Hu, Xiao-ni Zhong, Bin Peng, Yan Zhang, Hao Liang, Jiang-hong Dai, Ju-ying Zhang, Ai-long Huang

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

To investigate the associations between the perceived barriers and benefits of using HIV pre-exposure prophylaxis medication, including worries about the side effects, disliking taking drugs, perceived burden of taking medication, positive expectations as to the efficacy of the drugs, favourable doctor-patient relationships, and medication adherence among men who have sex with men (MSM) to provide a target for improving medication adherence and reducing HIV infection among MSM.

Methods

MSM were recruited in western China from April 2013 to October 2014, administered oral tenofovir (TDF) daily and followed up every 12 weeks for 2 years. At each follow-up, the medication rate was calculated based on the self-reported number of missed doses over 2 weeks, and then, the medication adherence was evaluated. The barriers and benefits perceived during medication were obtained by a self-administered questionnaire, and their effects on medication adherence were analysed by linear mixed models.

Results

A total of 411 participants were enrolled in this study, and 1561 follow-up observation points were obtained. The average medication rate was 0.62 ± 0.37, and the medication rate increased with longer follow-up (P < 0.05). The medication rate was higher among MSM who were divorced (compared to those who were unmarried, P < 0.0001). MSM with more positive expectations as to the efficacy of the drugs showed higher rates of medication (P < 0.0001), while those who were more worried about side effects had a lower medication rate (P = 0.0208). In contrast, the dislike of taking the drugs and the burden perceived during medication had no effects on the actual medication rate of taking TDF (P > 0.05).

Conclusion

How to obtain and maintain high medication adherence among MSM is the key to the PrEP intervention strategy for effective reduction of HIV infection. For MSM in China, we should deepen their understanding of the effectiveness and safety of PrEP and increase their confidence in PrEP, thereby improving their medication adherence.

Trial registration

ChiCTR-TRC-13003849. Registered on 24/06/2013.
Literature
3.
go back to reference Zhang L, et al. HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis. 2013;13(11):955–63.CrossRef Zhang L, et al. HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis. 2013;13(11):955–63.CrossRef
4.
go back to reference Qin Q, et al. Spatial analysis of the human immunodeficiency virus epidemic among men who have sex with men in China, 2006-2015. Clin Infect Dis. 2017;64(7):956–63.CrossRef Qin Q, et al. Spatial analysis of the human immunodeficiency virus epidemic among men who have sex with men in China, 2006-2015. Clin Infect Dis. 2017;64(7):956–63.CrossRef
5.
go back to reference NCAIDS N. Update on the AIDS/STD epidemic in China in December. Chinese J AIDS&STD. 2017;24(2):111. NCAIDS N. Update on the AIDS/STD epidemic in China in December. Chinese J AIDS&STD. 2017;24(2):111.
6.
go back to reference Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380(9839):325.CrossRef Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380(9839):325.CrossRef
7.
go back to reference Smith DK, et al. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Korean J Ophthalmol. 2014;27(4):282–7. Smith DK, et al. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Korean J Ophthalmol. 2014;27(4):282–7.
8.
go back to reference Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRef Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRef
9.
go back to reference Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820.CrossRef Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820.CrossRef
10.
go back to reference Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRef Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRef
11.
go back to reference Karim QA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef Karim QA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
12.
go back to reference Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRef Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRef
13.
go back to reference Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9(1):e86584.CrossRef Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9(1):e86584.CrossRef
14.
go back to reference Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of Serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.CrossRef Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of Serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.CrossRef
15.
go back to reference Marrazzo JM, et al. Tenofovir-based Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef Marrazzo JM, et al. Tenofovir-based Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef
16.
go back to reference Muchomba FM, et al. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.CrossRef Muchomba FM, et al. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.CrossRef
17.
go back to reference Van DL, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;308(9):411–22. Van DL, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;308(9):411–22.
18.
go back to reference Mehrotra ML, et al. The effect of depressive symptoms on adherence to daily Oral PrEP in men who have sex with men and transgender women: a marginal structural model analysis of the iPrEx OLE study. Aids & Behavior. 2016;20(7):1527–34.CrossRef Mehrotra ML, et al. The effect of depressive symptoms on adherence to daily Oral PrEP in men who have sex with men and transgender women: a marginal structural model analysis of the iPrEx OLE study. Aids & Behavior. 2016;20(7):1527–34.CrossRef
19.
go back to reference Defechereux PA, et al. Depression and Oral FTC/TDF pre-exposure prophylaxis (PrEP) among men and transgender women who have sex with men (MSM/TGW). Aids & Behavior. 2016;20(7):1478–88.CrossRef Defechereux PA, et al. Depression and Oral FTC/TDF pre-exposure prophylaxis (PrEP) among men and transgender women who have sex with men (MSM/TGW). Aids & Behavior. 2016;20(7):1478–88.CrossRef
20.
go back to reference Minnis AM, et al. Pre-exposure prophylaxis adherence measured by plasma drug level in MTN-001: comparison between vaginal gel and oral tablets in two geographic regions. Aids & Behavior. 2016;20(7):1541–8.CrossRef Minnis AM, et al. Pre-exposure prophylaxis adherence measured by plasma drug level in MTN-001: comparison between vaginal gel and oral tablets in two geographic regions. Aids & Behavior. 2016;20(7):1541–8.CrossRef
21.
go back to reference Zeng X. Tenofovir-based oral PrEP prevents HIV infection among men who have sex with men in western China:a multicenter, randomized, controlled clinical trial: Chongqing Medical University; 2013 (in Chinese). Zeng X. Tenofovir-based oral PrEP prevents HIV infection among men who have sex with men in western China:a multicenter, randomized, controlled clinical trial: Chongqing Medical University; 2013 (in Chinese).
22.
go back to reference O’Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Review. 1992;49(4):435.CrossRef O’Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Review. 1992;49(4):435.CrossRef
23.
go back to reference Bakken S, et al. Relationships between perception of engagement with health care provider and demographic. AIDS Patient Care STDs. 2000;14(4):189–97.CrossRef Bakken S, et al. Relationships between perception of engagement with health care provider and demographic. AIDS Patient Care STDs. 2000;14(4):189–97.CrossRef
24.
go back to reference Zhang Y, et al. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. Aids Patient Care & Stds. 2013;27(3):137.CrossRef Zhang Y, et al. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. Aids Patient Care & Stds. 2013;27(3):137.CrossRef
25.
go back to reference Peng B, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. Hiv/aids. 2012;4(default):149.PubMed Peng B, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. Hiv/aids. 2012;4(default):149.PubMed
26.
go back to reference Holloway IW, et al. Facilitators and barriers to pre-exposure prophylaxis willingness among young men who have sex with men who use geosocial networking applications in California. Aids Patient Care & Stds. 2017;31(12):517.CrossRef Holloway IW, et al. Facilitators and barriers to pre-exposure prophylaxis willingness among young men who have sex with men who use geosocial networking applications in California. Aids Patient Care & Stds. 2017;31(12):517.CrossRef
27.
go back to reference Gengiah TN, et al. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014;36(1):70–85.CrossRef Gengiah TN, et al. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014;36(1):70–85.CrossRef
28.
go back to reference Kebaabetswe PM, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily Oral Tenofovir/Emtricitibine as pre-exposure prophylaxis (Prep) clinical trial, Botswana, 2007-2010. Aids & Behavior. 2015;19(5):758–69.CrossRef Kebaabetswe PM, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily Oral Tenofovir/Emtricitibine as pre-exposure prophylaxis (Prep) clinical trial, Botswana, 2007-2010. Aids & Behavior. 2015;19(5):758–69.CrossRef
29.
go back to reference Mustanski B, et al. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. Aids Behavior. 2013;17(6):2173–9.CrossRef Mustanski B, et al. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. Aids Behavior. 2013;17(6):2173–9.CrossRef
30.
go back to reference Mutua G, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.CrossRef Mutua G, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.CrossRef
31.
go back to reference Skoler-Karpoff S, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.CrossRef Skoler-Karpoff S, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.CrossRef
32.
go back to reference Williams AB, et al. A proposal for quality standards for measuring medication adherence in research. Aids & Behavior. 2013;17(1):284–97.CrossRef Williams AB, et al. A proposal for quality standards for measuring medication adherence in research. Aids & Behavior. 2013;17(1):284–97.CrossRef
33.
go back to reference Abaasa A, et al. Utility of different adherence measures for PrEP: patterns and incremental value. Aids & Behavior. 2017;22(5):1–9. Abaasa A, et al. Utility of different adherence measures for PrEP: patterns and incremental value. Aids & Behavior. 2017;22(5):1–9.
Metadata
Title
Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China
Authors
Ying Hu
Xiao-ni Zhong
Bin Peng
Yan Zhang
Hao Liang
Jiang-hong Dai
Ju-ying Zhang
Ai-long Huang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3497-7

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue